Highlights

• EVE Health Group has executed a binding compounding agreement with Optimal Pharmacy Plus Stafford, establishing an exclusive Australian channel for its men's sexual health range ahead of full product registration.

• The company's Libbo vardenafil oral dissolving film is currently available via the TGA's Special Access Scheme, with a pilot pharmacokinetic study targeted for the fourth quarter of 2026.

• EVE's patent-pending nano-emulsion platform underpins a pipeline spanning erectile dysfunction, premature ejaculation, anticoagulants, and lipid-lowering agents.

• Under the compounding agreement, EVE retains full intellectual property rights and receives the majority of profit after direct costs, with Optimal acting as the exclusive Australian compounder.

EVE Health Group Limited (ASX:EVE), an ASX-listed Australian life sciences company trading under the ticker EVE, presented a Business update to investors on 12 November 2026 outlining progress across its patent-pending pharmaceutical reformulation platform. The company is focused on improving the delivery characteristics of established generic medicines — particularly those where patient discontinuation is driven by slow onset times, food interactions, or inconvenient tablet formats that require planning around meals and timing. Its lead product, Libbo, is a vardenafil oral dissolving film designed to deliver the established active ingredient transmucosally, with formulation-based onset characteristics that the company believes may offer an advantage over conventional swallowed tablets for patients who have been poorly served by existing products. Libbo targets a portion of the significant proportion of patients who discontinue conventional phosphodiesterase type 5 inhibitors within the first year of treatment, a patient group that the company views as a natural addressable market for a faster-acting, more convenient delivery format.

The Libbo Product and Its Commercial Pathway

Libbo is currently available to Australian patients through the Therapeutic Goods Administration's Special Access Scheme pathway, which permits prescribing of unapproved products by treating practitioners on a case-by-case basis. EVE has established a commercial infrastructure supporting this route to patients, including partnerships with telehealth providers and a licensed pharmacy fulfilment network operating via the LibX.com.au platform. Building on this foundation, the company has now signed a binding master compounding and profit share agreement with Optimal Pharmacy Plus Stafford, executed on 10 November 2026, which provides a separate and complementary commercial channel for a range of compounded men's sexual health formulations. The agreement covers vardenafil formulations for erectile dysfunction, a premature ejaculation product using the same nano-emulsion base, and a combined preparation targeting both conditions in a single format. Under the terms of the agreement, EVE retains all intellectual property rights including patent-pending formulation technology, Optimal is restricted from compounding competing formulations during the term, and EVE receives the majority of profit available for distribution after direct costs. First Supply under the agreement is conditional on completion of technology transfer and validation steps.

Compounding Agreement with Optimal Pharmacy

Beyond the Libbo product and its associated compounding range, EVE's nano-emulsion platform is being applied to a broader pipeline of established medicines approaching or past Patent expiry, where improved delivery science could translate into meaningful patient benefits. The company has identified a number of high-value molecules as potential reformulation candidates, including an apixaban reformulation in pre-bioequivalence development targeting the anticoagulant category, and lipid-lowering agents currently in development or early-stage screening. The pivot to medicines with large existing patient populations and established efficacy profiles is designed to reduce overall development risk while targeting meaningful improvement in delivery outcomes for patients. This approach leverages the bioequivalence regulatory pathway, which is intended to be faster and less costly than conventional new drug development, since the safety and efficacy of the active ingredient itself is already established.

Platform Pipeline and Upcoming Milestones

Looking at the trajectory of the company's clinical and regulatory programme, several near-term milestones are on the horizon. The pilot pharmacokinetic study for Libbo was targeted for the fourth quarter of 2026, with data expected in early 2027 to support the design of a formal bioequivalence study. The pivotal bioequivalence study itself is targeted to commence in the first quarter of 2027, subject to satisfactory pilot outcomes, with a potential regulatory registration submission possible in the second half of 2027 if clinical and regulatory outcomes are favourable. Preliminary partner discussions covering distribution following registration were described as underway across several international markets. The company's overall model is characterised by a capital-light, partner-led commercial structure, with EVE focused on research, regulatory execution, and intellectual property development rather than Manufacturing or distribution infrastructure, allowing it to scale through established partners as the product portfolio matures toward full registration. For observers of the Australian life sciences sector, EVE Health Group's approach to pharmaceutical reformulation occupies a niche that is distinct from both traditional generics manufacturers and novel drug developers. By focusing on improving the delivery of well-established molecules rather than developing entirely new chemical entities, the company targets a development pathway that is typically shorter and less capital-intensive than conventional pharmaceutical R&D, while still offering a commercially meaningful point of differentiation for prescribers and patients. The challenge, as with any pharmaceutical development programme, lies in translating promising formulation science into clinical validation data that meets the standards of regulatory agencies, and in commercialising the resulting products through partner channels at a scale that generates sustainable returns. The milestones ahead — including the pilot study results, the bioequivalence study, and the registration submission — will be important markers of whether the company's platform science can be successfully translated into registered and commercially viable products.

Key Insights

Looking at the trajectory of the company's clinical and regulatory programme, several near-term milestones are on the horizon. The pilot pharmacokinetic study for Libbo was targeted for the fourth quarter of 2026, with data expected in early 2027 to support the design of a formal bioequivalence study. The pivotal bioequivalence study itself is targeted to commence in the first quarter of 2027, subject to satisfactory pilot outcomes, with a potential regulatory registration submission possible in the second half of 2027 if clinical and regulatory outcomes are favourable. Preliminary partner discussions covering distribution following registration were described as underway across several international markets. The company's overall model is characterised by a capital-light, partner-led commercial structure, with EVE focused on research, regulatory execution, and intellectual property development rather than manufacturing or distribution infrastructure, allowing it to scale through established partners as the product portfolio matures toward full registration. For observers of the Australian life sciences sector, EVE Health Group's approach to pharmaceutical reformulation occupies a niche that is distinct from both traditional generics manufacturers and novel drug developers. By focusing on improving the delivery of well-established molecules rather than developing entirely new chemical entities, the company targets a development pathway that is typically shorter and less capital-intensive than conventional pharmaceutical R&D, while still offering a commercially meaningful point of differentiation for prescribers and patients. The challenge, as with any pharmaceutical development programme, lies in translating promising formulation science into clinical validation data that meets the standards of regulatory agencies, and in commercialising the resulting products through partner channels at a scale that generates sustainable returns. The milestones ahead — including the pilot study results, the bioequivalence study, and the registration submission — will be important markers of whether the company's platform science can be successfully translated into registered and commercially viable products.